Kiwi Biosciences
YC S21Boston, US · Founded 2020 · 10 employees · 1 known investors
FODZYME develops an enzyme powder supplement that breaks down FODMAPs in food, particularly fructans found in garlic, onions, and wheat, for people with digestive sensitivities. The product targets individuals who need to manage FODMAP intolerance to improve their diet flexibility and quality of life.
Founders & leadership· Y Combinator alumni (S21)
Investors · 1
In the news
- Kiwi Biosciences - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2025
- Kiwi Biosciences - 2026 Company Profile, Funding, Competitors & Financials - Tracxntracxn.com · 2025
- Kiwi Biosciences Scores $1.5M Funding Boost to Launch FODZYME: A New Era for IBS Relief and Enjoyable Mealsleadsontrees.com · 2025
- Kiwi Biosciences (FODZYME) - Founder, CEO, Funding, Revenue & Company Details | Founded 2020insights.persana.ai · 2023
- Y Combinator-backed Kiwi Biosciences Launches Novel Portable Enzymes To Make Food Painless For 15% of the Planetprnewswire.com · 2022
- Kiwi Bio aims to free irritable bowel syndrome sufferers from restrictive diets – TechCrunchtechcrunch.com · 2021
- Kiwi Biosciences Funding | $1.2M Revenue | Complete Analysis | Extruct AIextruct.ai · 2020